PE20080995A1 - 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen - Google Patents
18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienenInfo
- Publication number
- PE20080995A1 PE20080995A1 PE2007000837A PE2007000837A PE20080995A1 PE 20080995 A1 PE20080995 A1 PE 20080995A1 PE 2007000837 A PE2007000837 A PE 2007000837A PE 2007000837 A PE2007000837 A PE 2007000837A PE 20080995 A1 PE20080995 A1 PE 20080995A1
- Authority
- PE
- Peru
- Prior art keywords
- methyl
- espirox
- androst
- contain
- espiroeteres
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Endocrinology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Cosmetics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
SE REFIERE A COMPUESTOS 18-METIL-19-NOR-ANDROST-4-EN-17,17-ESPIROETERES DE FORMULA (I) EN DONDE Z ES O, DOS ATOMOS DE H, =NOR, =NNHSO2R; R4 ES H, HALOGENO O TRIFLUOROMETILO; R6 Y R7 PUEDEN ESTAR EN POSICION a O ß Y SON INDEPENDIENTEMENTE H, ALQUILO(C1-C4) O ALQUENILO(C1-C4) LINEAL O RAMIFICADO O CICLOALQUILO. SON SELECCIONADOS: 18-METIL-15ß,16ß-METILEN-19-NOR-20-ESPIROX-4,6-DIEN-3-ONA, 18-METIL-6a,7a,15ß,16ß-DIMETILEN-19-NOR-20-ESPIROX-4-EN-3-ONA, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE ADEMAS PUEDEN CONTENER UN ESTROGENO, ETINILESTRADIOL, VALERATO DE ESTRADIOL, ESTROGENO CONJUGADO. ESTOS COMPUESTOS PRESENTAN UNA ACCION GESTAGENICA MAS POTENTE QUE LA DROSPIRENONA Y MENOR ACCION NATRIURETICA (ANTIMINERALOCORTICOIDE), SIENDO UTILES PARA LA ANTICONCEPCION, TRATAMIENTO DE TRASTORNOS PREMENSTRUALES COMO CEFALEAS, DEPRESION, RETENCION DE AGUA, MASTODINIA
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006030416A DE102006030416A1 (de) | 2006-06-29 | 2006-06-29 | 18-Methyl-19-nor-androst-4-en-17,17-spiroether (18-Methyl-19-nor-20-spirox-4-en-3-one) sowie diese enthaltende pharmazeutische Präparate |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20080995A1 true PE20080995A1 (es) | 2008-10-03 |
Family
ID=38626491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2007000837A PE20080995A1 (es) | 2006-06-29 | 2007-07-02 | 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen |
Country Status (41)
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102007063498A1 (de) * | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | 15,16-Methylen-steroid-17,17-Lactol-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
DE102007063496A1 (de) | 2007-12-29 | 2009-07-02 | Bayer Schering Pharma Aktiengesellschaft | 15,16-Methylen-17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-on-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
DE102008026793A1 (de) | 2008-06-02 | 2009-12-03 | Bayer Schering Pharma Aktiengesellschaft | C-Ring-substituierte Pregn-4-en-21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
WO2010066354A1 (de) * | 2008-12-12 | 2010-06-17 | Bayer Schering Pharma Aktiengesellschaft | VERWENDUNG VON 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATEN ZUR HERSTELLUNG EINES ARZNEIMITTELS IN DEPOT-FORM ZUR PARENTERALEN ANWENDUNG SOWIE DEPOT-ARZNEIMITTEL ENTHALTEND 17β-CYANO-18A-HOMO-19-NOR-ANDROST-4-EN-DERIVATE ZUR PARENTERALEN ANWENDUNG |
WO2012059594A1 (en) | 2010-11-04 | 2012-05-10 | Bayer Pharma Aktiengesellschaft | Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity |
TW201350122A (zh) * | 2012-04-23 | 2013-12-16 | Bayer Pharma AG | 18-甲基-15β,16β-亞甲基-19-降-20-螺氧-4-烯-3-酮的子宮內用途,包含18-甲基-15β,16β-亞甲基-19-降-20-螺氧-4-烯-3-酮的子宮內系統,及其於避孕及婦科治療之用途 |
SG11201406583QA (en) * | 2012-04-23 | 2014-11-27 | Bayer Pharma AG | Application of 18-methyl-15ss,16ss-methylene-19-nor-20-spirox-4-en-3-one systems in the treatment of menorrhagia, as well as intrauterine systems containing 18-methyl-15ss,16ss-methylene-19-nor-20-spi |
WO2015055789A1 (en) * | 2013-10-17 | 2015-04-23 | Bayer Pharma Aktiengesellschaft | INTRAVAGINAL USE OF 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, INTRAVAGINAL RINGS COMPRISING 18-METHYL-15ß,16ß-METHYLENE-19-NOR-20-SPIROX-4-EN-3-ONES, AND USE THEREOF IN CONTRACEPTION |
KR20160072114A (ko) * | 2013-10-18 | 2016-06-22 | 베이어 오와이 | 자궁내 전달 시스템 |
CN105237605B (zh) * | 2014-07-11 | 2019-01-25 | 上海迪赛诺生物医药有限公司 | 一种用于合成孕二烯酮的中间体及其制备方法和应用 |
CN109575094B (zh) * | 2019-01-17 | 2021-01-26 | 浙江仙琚制药股份有限公司 | 替勃龙中间体的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3798213A (en) * | 1971-01-25 | 1974-03-19 | Merck & Co Inc | 7 alpha-methyl-20-spiroxane-3-ones and process |
DE3022337A1 (de) * | 1980-06-11 | 1982-01-07 | Schering Ag Berlin Und Bergkamen, 1000 Berlin | Praeparate zur kontrazeption und zur behandlung gynaekologischer stoerungen |
DE3111950A1 (de) | 1981-03-23 | 1982-09-30 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | 7(alpha)-alkoxycarbonyl-15(beta).16(beta)-methylen-4-androsten-3-one, verfahren zu ihrer herstellung und verwendung als arzneimittel |
DE3402329A1 (de) * | 1984-01-20 | 1985-08-01 | Schering AG, 1000 Berlin und 4709 Bergkamen | 6,6-ethylen-15,16-methylen-3-oxo-17(alpha)-pregn-4-en-21,17-carbolactone, verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate |
DE19651000A1 (de) * | 1996-12-01 | 1998-06-04 | Schering Ag | Oxyiminopregnancarbolactone |
EP1223174A3 (en) | 1996-12-11 | 2005-03-16 | G.D. Searle & Co. | Processes for preparation of 3-keto-7alpha-alkoxycarbonyl-delta-4,5- steroids and intermediates useful therein |
US6787531B1 (en) * | 1999-08-31 | 2004-09-07 | Schering Ag | Pharmaceutical composition for use as a contraceptive |
US8445469B2 (en) * | 2004-12-30 | 2013-05-21 | Bayer Intellectual Property Gmbh | 18-methyl-19-nor-17-pregn-4-ene-21,17-carbolactones, as well as pharmaceutical preparations that contain the latter |
DE102004063864A1 (de) * | 2004-12-30 | 2006-07-13 | Schering Ag | 18-Methyl-19-nor-17-pregn-4-en21,17-carbolactone, sowie diese enthaltende pharmazeutische Präparate |
-
2006
- 2006-06-29 DE DE102006030416A patent/DE102006030416A1/de not_active Withdrawn
-
2007
- 2007-06-28 US US11/769,952 patent/US7846917B2/en not_active Expired - Fee Related
- 2007-06-29 RS RS20110109A patent/RS51722B/en unknown
- 2007-06-29 DK DK07765033.1T patent/DK2038294T3/da active
- 2007-06-29 EP EP07765033A patent/EP2038294B1/de active Active
- 2007-06-29 CA CA2656443A patent/CA2656443C/en not_active Expired - Fee Related
- 2007-06-29 AT AT07765033T patent/ATE490967T1/de active
- 2007-06-29 CL CL200701919A patent/CL2007001919A1/es unknown
- 2007-06-29 CN CN2007800246245A patent/CN101511857B/zh not_active Expired - Fee Related
- 2007-06-29 ES ES07765033T patent/ES2357698T3/es active Active
- 2007-06-29 AR ARP070102908A patent/AR061736A1/es not_active Application Discontinuation
- 2007-06-29 JP JP2009517034A patent/JP5326085B2/ja not_active Expired - Fee Related
- 2007-06-29 AU AU2007263944A patent/AU2007263944B2/en not_active Ceased
- 2007-06-29 KR KR1020087031791A patent/KR101440640B1/ko active IP Right Grant
- 2007-06-29 RU RU2009102772/04A patent/RU2440365C2/ru not_active IP Right Cessation
- 2007-06-29 PL PL07765033T patent/PL2038294T3/pl unknown
- 2007-06-29 UY UY30451A patent/UY30451A1/es not_active Application Discontinuation
- 2007-06-29 TW TW096123940A patent/TWI413645B/zh not_active IP Right Cessation
- 2007-06-29 BR BRPI0713934-9A patent/BRPI0713934A2/pt not_active IP Right Cessation
- 2007-06-29 NZ NZ573951A patent/NZ573951A/en not_active IP Right Cessation
- 2007-06-29 MY MYPI20071041A patent/MY155015A/en unknown
- 2007-06-29 SI SI200730533T patent/SI2038294T1/sl unknown
- 2007-06-29 UA UAA200900433A patent/UA94952C2/uk unknown
- 2007-06-29 WO PCT/EP2007/005893 patent/WO2008000521A1/de active Application Filing
- 2007-06-29 MX MX2009000082A patent/MX2009000082A/es active IP Right Grant
- 2007-06-29 PT PT07765033T patent/PT2038294E/pt unknown
- 2007-06-29 DE DE502007005902T patent/DE502007005902D1/de active Active
- 2007-07-02 PE PE2007000837A patent/PE20080995A1/es not_active Application Discontinuation
-
2008
- 2008-12-15 IL IL195935A patent/IL195935A0/en not_active IP Right Cessation
- 2008-12-15 TN TNP2008000518A patent/TNSN08518A1/en unknown
- 2008-12-26 CO CO08137168A patent/CO6150134A2/es unknown
- 2008-12-29 HN HN2008001934A patent/HN2008001934A/es unknown
- 2008-12-29 EC EC2008009014A patent/ECSP089014A/es unknown
- 2008-12-29 DO DO2008000089A patent/DOP2008000089A/es unknown
-
2009
- 2009-01-05 CR CR10548A patent/CR10548A/es unknown
- 2009-01-22 MA MA31582A patent/MA30596B1/fr unknown
- 2009-01-28 ZA ZA200900673A patent/ZA200900673B/xx unknown
- 2009-01-28 NO NO20090459A patent/NO20090459L/no not_active Application Discontinuation
- 2009-03-05 GT GT200800307A patent/GT200800307A/es unknown
-
2010
- 2010-02-11 HK HK10101560.6A patent/HK1133659A1/xx not_active IP Right Cessation
-
2011
- 2011-03-04 HR HR20110161T patent/HRP20110161T1/hr unknown
- 2011-03-08 CY CY20111100261T patent/CY1111658T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20080995A1 (es) | 18-metil-19-nor-androst-4-en-17,17-espiroeteres(18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen | |
PE20060853A1 (es) | 18-metil-19-nor-17-pregn-4-en-21,17-carbolactonas, asi como preparaciones farmaceuticas que las contienen | |
AR057060A1 (es) | Composiciones de tanaproget que contienen etinil estradiol | |
PE20070327A1 (es) | Composicion que comprende una progestina y un estrogeno | |
BRPI0512993A (pt) | uso de um antagonista de pr, kit farmaceuticamente últil, e, método de contracepção em uma fêmea em idade de parto | |
BRPI0517752C1 (pt) | processo para a preparação de drospirenona | |
NZ609420A (en) | Fulvestrant compositions and methods of use | |
AR082998A1 (es) | Asociacion farmaceutica para tratar y/o prevenir mioma y/o endometriosis, uso de resveratrol y progestogeno, composicion farmaceutica para tratamiento y/o prevencion de mioma y/o endometriosis, medicamento para tratamiento y/o prevencion de mioma y/o endometriosis, kit y metodo para tratamiento y/o prevencion de mioma y/o endometriosis | |
PE20061415A1 (es) | Composicion farmaceutica que contiene gestagenos y/o estrogenos y 5-metil-(6s)-tetrahidrofolato | |
ATE311204T1 (de) | Estrogen-zyklodextrin komplexe-zusammensetzungen | |
BR112012009306A2 (pt) | método para regeneração de mielina em um paciente | |
CR10732A (es) | Uso de valerato de estradiol o 17 b- estradiol en combinacion con dienogest en una terapia oral para mantener y / o incrementar la libido femenina | |
BR0109983A (pt) | Estratrienos substituìdos por 8.beta-hidrocarbila como estrogênios seletivamente eficientes | |
AR095691A1 (es) | FORMULACIÓN DE L-5-METILTETRAHIDROFOLATO DE CALCIO AMORFO (L-5-MTHF-Ca), PROCEDIMIENTO, USO | |
ECSP055530A (es) | Estratrienos 9-alfa-sustituidos como estrógenos de eficacia selectiva | |
RS90504A (en) | C-17 spirolactonization and 6,7 oxidation of steroids | |
RU2010100331A (ru) | ПРОИЗВОДНОЕ 17β-ЦИАНО-19-НОР-АНДРОСТ-4-ЕНА, ЕГО ПРИМЕНЕНИЕ И ЛЕКАРСТВЕННЫЕ СРЕДСТВА, СОДЕРЖАЩИЕ УКАЗАННОЕ ПРОИЗВОДНОЕ | |
AR043013A1 (es) | Composicion farmaceutica destinada al tratamiento de la endometriosis | |
CR11211A (es) | Estratienos 8-beta-sustituidos como estrogenos de accion selectiva | |
MXPA05012841A (es) | Composicion que comprende antagonistas de receptores de progesterona y antiestrogenos puros para la profilaxis y el tratamiento de enfermedades dependientes de hormonas. | |
ATE419855T1 (de) | Therapie für hormonersatz und depression enthaltend dienogest | |
AR018313A1 (es) | Kit anticonceptivo que comprende medios para la administracion diaria de un agente anticonceptivo, uso de un compuesto esteroide que tiene un perfil deactividad que combina inherentemente las actividades progestagenicas y estrogenicas y un metodo anticonceptivo | |
DE60311779D1 (de) | Steroidische chinole als antioxidantien-vorstufen | |
AR070302A1 (es) | Composicion farmaceutica de un sistema de liberacion vaginal de esteroides | |
PE20020709A1 (es) | Composiciones de complejos de estrogeno-ciclodextrina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |